Annals of Biomedical Engineering

, Volume 22, Issue 2, pp 184–193 | Cite as

An analysis of the contact phase of blood coagulation: Effects of shear rate and surface are intertwined

  • Kate Gregory
  • Diran Basmadjian


This work analyzes, for the first time, the combined role of blood flow, protein transport and the reaction network of the contact phase up to the “common pathway” of the blood coagulation cascade. The model is comprised of a set of 20 dominant reactions with 11 components. Systems of ODEs reducible to 4 coupled equations describe rigorously the dynamic behavior, while systems of algebraic equations, reducible to a single polynomial equation, model the steady state concentrations of the coagulants. The analysis showed that there is never more than onestable steady state. This is in contrast to the analysis of common pathway that gives rise to multiple concentration states. It also revealed a general robustness of the system to changes in procoagulant concentrations, inhibition rates and most activation rate constants. The system is largely impervious to the level of activated Factor XII, given that a trace (non-zero) level is present. In contrast, the system displays a dual response to flow and surface activity: A change in either of these factors alone can promote, have no effect on, or (in the case of flow) impede the progress of coagulation, depending on the value of the other factor. Their effects must therefore be examined in unison. These results may help resolve contradictory findings attributed to one or the other factor alone.


Mathematical model Factor XII Kallikrein HMWK Cascade Mass transfer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Basmadjian, D. The effect of flow and mass transport in thrombogenesis. Ann. Biomed. Eng. 18:685–709; 1990.CrossRefPubMedGoogle Scholar
  2. 2.
    Boyce, W.E.; DiPrima, R.C. Elementary differential equations and boundary value problems. 3rd ed. New York: John Wiley; 1977.Google Scholar
  3. 3.
    Colman, R.W.; Schmaier, A.H. The contact activation system: Biochemistry and interactions of these surface mediated defense reactions. CRC Crit. Rev. in Onc. Hem 5(1): 57; 1986.Google Scholar
  4. 4.
    Conley, C.L.; Hartmann, R.C.; Morse, W.I. The clotting behavior of human platelet-free plasma: Evidence for the existence of a plasma thrombo-plastin. J. Clin. Inv. 28:340–352; 1949.Google Scholar
  5. 5.
    Gregory, K.M. Mathematical modelling of the contact phase of blood coagulation. Ph.D. Thesis. University of Toronto, Toronto, Ontario, Canada, 1992.Google Scholar
  6. 6.
    Griep, M.A.; Fujikawa, K.; Nelsestuen, G.L. Possible basis for the apparent surface selectivity of the contact activation of human blood coagulation Factor XII. Biochemistry 25: 6688–6694; 1986.CrossRefPubMedGoogle Scholar
  7. 7.
    Kaplan, A.P.; Silverberg, M. The coagulation-kinin pathway of human plasma. Blood 70:1–15; 1987.PubMedGoogle Scholar
  8. 8.
    Margolis, J. The kaolin clotting time. J. Clin. Pathology 11:406–409; 1958.Google Scholar
  9. 9.
    Meijers, J.C.M.; Vlosswijk, R.A.A.; Reeves, B.E.A.; Esnouf, M.P. The activation of the contact phase of coagulation by physiologic surfaces in plasma: The effect of negatively charged liposomal vesicles. Blood 73:1525–1533; 1989.Google Scholar
  10. 10.
    Ratnoff, O.D.; Busce, F.J.; Sheon, R.P. The demise of John Hageman. N. Engl. J. Med. 279:760; 1968.Google Scholar
  11. 11.
    Rosing, J.; Tans, G.; Griffin, J.H. Surface dependent activation of human factor XII (Hageman factor) by kallikrein and its light chain. Eur. J. Biochemistry 151:531–538; 1985.Google Scholar
  12. 12.
    Schapira, M.; Scott, C.F.; Colman, R.W. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Inv. 69:462–468; 1982.Google Scholar
  13. 13.
    Scott, C.F.; Schapira, M.; James, H.L.; Cohen, A.B.; Colman, R.W. Inactivation of factor XIa by plasma protease inhibitors—predominant role alpha-1-antitrypsin inhibitor and protective effect of HMWK. J. Clin. Inv. 69:844–852; 1982.Google Scholar
  14. 14.
    Scott, C.F.; Silver, L.D.; Schapira, M.; Colman, R.W. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity: Evidence that this molecular exists as a pro-cofactor. J. Clin. Inv. 73:954–962; 1984.Google Scholar
  15. 15.
    Silverberg, M.; Kaplan, A.P. Enzymatic activities of activated and zymogen forms of human Hageman factor. Blood 60:64–70; 1982.PubMedGoogle Scholar
  16. 16.
    Soons, H.; Janssen-Claessen, T.; Tans, G.; Hemker, H.C. Inhibition of factor XIa by antithrombin III. Biochemistry 26:4624–4629, 1987.CrossRefPubMedGoogle Scholar
  17. 17.
    Tait, J.F.; Fujikawa, K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J. Biol. Chem. 262: 11651–11656; 1987.PubMedGoogle Scholar
  18. 18.
    Tans, G.; Rosing, G.; Griffin, J.H. Sulfatide dependent autoactivation of human blood coagulation factor XII (Hageman factor). J. Biol. Chem. 258:8215–8222; 1983.PubMedGoogle Scholar
  19. 19.
    Turitto, V.T. Blood viscosity, maas transport, and thrombogenesis. Prog. Hemost. Thromb. 6:139–177; 1982.PubMedGoogle Scholar
  20. 20.
    van der Graaf, F.; Koedam, J.A.; Griffin, J.H.; Bouma, B.N. Interaction of human plasma kallikrein and its light chain with Cl inhibitor. Biochemistry 22:4860–4866; 1983.PubMedGoogle Scholar
  21. 21.
    Vroman, L.; Adams, A.L.; Fischer, G.C.; Munoz, P.C. Interaction of high molecular weight kininogen, factor XII and fibrinogen in plasma at surfaces. Blood 55:156–159; 1980.PubMedGoogle Scholar
  22. 22.
    Weiss, H.J.; Turitto, V.T.; Vicic, W.J.; Baumgartner, H.R. Fibrin formation, fibrinopeptide. A release and platelet thrombus dimensions on subendothelium exposed to flowing native blood: Greater in factor XII and XI than in factor VIII and IX deficiency. Blood 63:1004–1014; 1984.PubMedGoogle Scholar

Copyright information

© Biomedical Engineering Society 1994

Authors and Affiliations

  • Kate Gregory
    • 1
  • Diran Basmadjian
    • 1
  1. 1.Department of Chemical Engineering and Applied ChemistryUniversity of TorontoTorontoCanada

Personalised recommendations